FDA and Competitiveness Council
Executive Summary
Rep. Weiss (D-N.Y.) tentatively schedules an oversight hearing for March 19 before House Intergovernmental Relations Subcommittee on the influence of the Vice President's Council on Competitiveness on FDA policy decisions. Rep. Waxman (D-Calif.) is said to be considering scheduling a similar hearing for March 24 before House Health Subcommittee on the subject.